SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending as investors digest news of significant debt-to-equity conversions by leadership and board members, signaling strong insider conviction ahead of upcoming quarterly results. The community is actively debating the impact of these financial maneuvers on the balance sheet alongside the stock's potential as a key supplier for high-profile defense programs and anticipated aerospace partnerships.

NKN is building the largest blockchain for network sharing.

New Kind of Network

NKN is capturing market attention as traders speculate on potential partnership rumors and a recently announced token buyback program. While some members of the community express frustration over past price action and delisting concerns, others are actively accumulating the asset, viewing it as a low-cap opportunity with potential for a short-squeeze recovery.

Pan American Silver Corp. engages in the operation, development, and exploration of silver and gold producing properties and assets. It operates through the Silver and Gold segments. The Silver segment includes La Colorada, Huaron, Morococha, San Vicente, and Manantial Espejo mines. The Gold segment refers to the Dolores, Shahuindo, La Arena, Timmins West, and Bell Creek mines. The company was founded by Ross J. Beaty and John H. Wright on March 7, 1979 and is headquartered in Vancouver, Canada.

Pan American Silver Corp

Pan American Silver (PAAS) is trending as investors capitalize on surging silver prices and production growth, with the community closely tracking the company's strategic MAG Silver acquisition and potential progress at the Escobal mine. Traders are actively debating the stock's role as a high-torque leverage play on the precious metals supercycle, often citing the contrast between paper silver volatility and the company's strong fundamental cash flow.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is currently a focal point for investors due to persistent speculation regarding a potential buyout by major shareholders and intense activity from short sellers. The community remains deeply divided, with some betting on a long-term turnaround fueled by international expansion and an attractive dividend yield, while others are frustrated by the lack of permanent CEO leadership and ongoing operational struggles.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM Integrated Shipping Services is trending following the announcement of a merger agreement where Hapag-Lloyd will acquire the company for $35 per share in an all-cash deal. Investors are actively discussing the implications of the acquisition, potential short squeeze dynamics, and the impact of the pending regulatory and Israeli government approvals on the deal's timeline.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin ($BNKR) is attracting significant investor attention as a key infrastructure play for autonomous onchain AI agents within the Base ecosystem. Community sentiment remains bullish, with many users focusing on the project's growing utility, recurring revenue from transaction fees, and the strategic expansion of its agent-based trading capabilities.

Maul Coin

Maul Coin is trending as the community actively builds momentum and promotes the project across platforms in anticipation of gaining official charting support. Investors are focused on grassroots growth, burning supply, and maintaining community-driven support levels to establish the coin as a long-term meme project.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors bet on potential utility-driven growth, fueled by anticipation surrounding an upcoming industry conference and speculation about a future collaboration with Ripple. The community remains divided, with long-term holders highlighting recent ecosystem scaling and burn mechanics while skeptics dismiss the price action as a recurring pattern of volatility and speculative pumping.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is currently trending as investors debate the impact of new value-driven menu strategies and aggressive global expansion plans against ongoing consumer spending headwinds and margin pressures. The community remains divided, with some highlighting the stock's defensive appeal during market volatility, while others point to concerns regarding menu pricing, product perception, and executive leadership.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont Corp is currently in the spotlight as investors digest impressive quarterly earnings characterized by record free cash flow and a stronger dividend outlook. While the broader community remains bullish on the stock's long-term leverage to rising gold prices and geopolitical instability, some market participants are debating the impact of the company's production guidance and the volatility often associated with the precious metals sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alto Neuroscience (NYSE:ANRO) Given New $38.00 Price Target at Robert W. Baird

Robert W. Baird decreased their price target on shares of Alto Neuroscience from $41.00 to $38.00 and set an "outperform" rating on the stock in a research note on Thursday...

<ul class="summary-bullets"><li>H.C. Wainwright said the failure of ALTO-101 in its Phase 2 study does not change its overall view on Alto Neuroscience.</li><li>Baird cut Alto’s price target to $38 from $41 but said the company’s depression pipeline remains the key driver of its valuation.</li><li>Jones Research’s latest price target implies a potential 100% upside to the stock’s current price.</li></ul>Shares of Alto Neuroscience (ANRO) slid about 7% on Thursday after disappointing results from a schizophrenia treatment study prompted multiple brokerages to become more cautious on the stock.On Wednesday, Alto Neuroscience <a href="https://stocktwits.com/news-articles/markets/equity/alto-neuroscience-schizophrenia-study-fails/cZ7HygQRIFi">said</a> its experimental schizophrenia drug ALTO-101 failed to meet key goals in a Phase 2 Proof-of-Concept study. ALTO-101 did not show meaningful improvements in brain activity or cognitive measures compared to placebo.As a result, the biotech firm will not continue developing the drug for this use and will shift focus to other programs, including ALTO-207 for treatment-resistant depression. The company is also exploring partnership opportunities for a modified version of ALTO-101 that showed better safety and drug behavior.<h2 class="st-heading-2">Analyst Sees Pullback As Attractive Entry Point</h2>Jones Research cut Alto Neuroscience’s price target to $44 from $49, but kept a ‘Buy’ rating, according to The Fly. This implies a potential 100% upside to the stock’s current price of around $22.Analyst Justin Walsh said that while the stock’s weakness is justified, the market is underestimating Alto’s broader pipeline and sees the pullback as an attractive entry point.H.C. Wainwright said the failure of ALTO-101 in its Phase 2 study does not change its overall view on Alto Neuroscience, as the program was not a key part of its valuation, according to The Fly. The brokerage also highlighted the company’s strong cash position of $275 million, which supports its pipeline. H.C. Wainwright maintained its ‘Buy’ rating and $50 price target.Baird cut the company’s price target to $38 from $41 and maintained an ‘Outperform’ rating. Analyst Brian Skorney called the ALTO-101 Phase 2 failure disappointing, though expectations were already modest given the challenges in schizophrenia treatment. The firm said Alto’s depression pipeline remains the key driver of its valuation.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Despite the intraday decline, retail sentiment for <a href="https://stocktwits.com/symbol/ANRO">ANRO</a> on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.One user had expected a bigger drop.<stembedurl>http://stocktwits.com/Stef_DL/message/649289943</stembedurl>Year-to-date, the stock has gained more than 20%.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/snbr-stock-on-track-to-decline-for-12th-straight-session/cZ7x67bRI8o">SNBR Stock On Track To Decline For 12th Straight Session – Retail Sees Buying Opportunity If Stock Dips Below $1</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alto Neuroscience logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point

Alto Neuroscience’s experimental schizophrenia drug ALTO-101 failed to meet key goals in a Phase 2 study, leading to price target cuts from multiple brokerages.

Equity

HC Wainwright Reaffirms Buy Rating for Alto Neuroscience (NYSE:ANRO)

HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Alto Neuroscience in a research note on Thursday...

JonesTrading Issues Pessimistic Forecast for Alto Neuroscience (NYSE:ANRO) Stock Price

JonesTrading reduced their price target on shares of Alto Neuroscience from $49.00 to $44.00 and set a "buy" rating on the stock in a research report on Thursday...

Alto Neuroscience (NYSE:ANRO) Shares Gap Down After Analyst Downgrade

Alto Neuroscience (NYSE:ANRO) Shares Gap Down After Analyst Downgrade...

Wedbush Lowers Alto Neuroscience (NYSE:ANRO) Price Target to $21.00

Wedbush reduced their target price on Alto Neuroscience from $22.00 to $21.00 and set a "neutral" rating on the stock in a report on Thursday...

Alto Neuroscience (NYSE:ANRO) Earns Buy Rating from Chardan Capital

Chardan Capital reissued a "buy" rating and set a $30.00 target price on shares of Alto Neuroscience in a research report on Thursday...

Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Dow futures down 400 points, Alto Neuroscience shares dip 13.6% after Phase 2 trial results, other stocks also falling in pre-market trading.read more...

<ul class="summary-bullets"><li>Alto will now focus on its other programs including ALTO-207 in development for treatment -resistant depression.</li><li>The company said that it also intends to explore partnering opportunities for a modified-release oral formulation of ALTO-101 that it has developed.</li></ul>Shares of Alto Neuroscience, Inc. (ANRO) fell as much as 10% after hours on Wednesday after the company said that its experimental drug for the treatment of schizophrenia failed to achieve statistical significance on key goals in a mid-stage study.The company was studying ALTO-101 for the treatment of cognitive impairment associated with schizophrenia. However, no statistically significant changes were detected on primary electroencephalography or cognitive endpoints as compared to placebo, the company said.<h2 class="st-heading-2">Plans Ahead</h2>As a result, the company does not intend to independently advance ALTO-101 in CIAS anymore, it said, while adding that it would now focus on its other programs including ALTO-207 in development for treatment -resistant depression. Alto is looking to initiate a mid-stage trial for &nbsp;ALTO-207 in the first half of 2026. &nbsp;The company said that it now intends to explore partnering opportunities for a modified-release oral formulation of ALTO-101 that it has developed. The formulation has demonstrated an improved pharmacokinetic and tolerability profile when compared to the immediate-release formulation, Alto said, while adding that it believes the formulation may offer potential benefits across several therapeutic areas.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ANRO &nbsp;stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user noted the company’s balance sheet, terming it an “easy short.”<stembedurl>https://www.stocktwits.com/Shortski/message/649224122</stembedurl>The company said earlier this month that it had cash, cash equivalents, and restricted cash of approximately $177 million as of the end of 2025, expected to support its planned operations into 2028.Another user termed the selloff an “overreaction.”<stembedurl>https://www.stocktwits.com/RazorbackAJ/message/649224026</stembedurl> <a href="https://stocktwits.com/symbol/ANRO">ANRO stock</a> has gained 32% this year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-agpu-stock-rise-today/cZ7HyVtRIF0">Why Did AGPU Stock Rise 120% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ANRO Stock Falls After Hours On Failed Schizophrenia Study Results

Alto Neuroscience does not intend to independently advance ALTO-101 in CIAS anymore, it said. 

Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced topline data from its Phase 2...

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

ANRO
Alto Neuroscience Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ANRO News

ANROAlto Neuroscience Inc.